Novartis introduces Lucentis® in state of the art pre-filled syringe
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which received European approval in October 2013, is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 24, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Ophthalmology Latest News Source Type: news

Novartis Launches Lucentis In Intraocular Injection
Novartis announced it is launching Lucentis (ranibizumab) in pre-filled syringe (PFS) formulation designed for intraocular injection in Germany. The product will be launched in other markets throughout this year. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 21, 2014 Category: Pharmaceuticals Source Type: news

Ranibizumab Treatment for Neovascular AMDRanibizumab Treatment for Neovascular AMD
Are there risk factors for being a 'reduced responder' to ranibizumab treatment for AMD, and if so, what should clinicians be aware of? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 26, 2014 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Japanese authorities approve fourth indication for Genentech-Novartis' eye drug Lucentis
The Japanese regulatory bodies have approved Lucentis (ranibizumab) for a fourth indication for treatment of patients with diabetic macular edema (DME), a major cause of vision loss among diabetic patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 25, 2014 Category: Pharmaceuticals Source Type: news

Ranibizumab and Long-Term Diabetic Macular Edema OutcomesRanibizumab and Long-Term Diabetic Macular Edema Outcomes
The benefits of individualized ranibizumab treatment for diabetic macular edema (DME) persist for at least three years, according to results from the RESTORE extension study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 17, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Bevacizumab vs Ranibizumab: Cost-Effectiveness for AMDBevacizumab vs Ranibizumab: Cost-Effectiveness for AMD
Bevacizumab is more cost-effective than ranibizumab for the treatment of newly diagnosed neovascular macular degeneration, according to a mathematical model. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 14, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Developments in the treatment of AMD
Eylea (aflibercept) is a new anti-vascular endothelial growth growth factor inhibitor that is as effective and safe as ranibizumab in the treatment of neovascular age-related macular degeneration (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 14, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news

Aerpio doses first patient in Phase II trial of diabetic macular edema drug AKB-9778
US-based clinical-stage biopharmaceutical firm Aerpio Therapeutics has dosed the first patient in a Phase II trial designed to evaluate AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for treatment of diabetic macular… (Source: Drug Development Technology)
Source: Drug Development Technology - February 14, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers strong 2013 results
Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics sales up 4% on strong Professional Diagnostics performance (Source: Roche Investor Update)
Source: Roche Investor Update - January 30, 2014 Category: Pharmaceuticals Source Type: news

AMD: Gene Variants Predict Response to Anti-VEGF DrugAMD: Gene Variants Predict Response to Anti-VEGF Drug
Minor alleles of the vascular endothelial growth factor 2 receptor gene predict response to ranibizumab treatment for wet AMD. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab for AMD: Dose and FrequencyRanibizumab for AMD: Dose and Frequency
The HARBOR study compared the efficacy and safety of 2 doses and 2 injection frequencies in patients with age-related macular degeneration. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2013 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Ranibizumab With and Without Ketorolac Eyedrops for AMDRanibizumab With and Without Ketorolac Eyedrops for AMD
Is ranibizumab more effective with or without the addition of ketorolac eyedrops in the treatment of exudative AMD? This new study takes a look. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

NICE says yes to Lucentis for myopic CNV in fast tracked draft final guidance
In a Final Appraisal Determination (FAD) published October 25, The National Institute for Health and Care Excellence (NICE) has recommended that Lucentis® (ranibizumab) be approved for use within the NHS in England and Wales as an option to treat people with visual impairment due to choroidal neovascularisation associated with pathological myopia (myopic CNV)6. Myopic CNV is the growth of abnormal leaky blood vessels in the back of the eye in high myopia (severe near sightedness)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 28, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Laser Reduces Retreatment in Diabetic Macular EdemaLaser Reduces Retreatment in Diabetic Macular Edema
Laser therapy added to ranibizumab significantly reduced the need for injections in patients with diabetic macular edema. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Cancer drug can treat blindness finds HTA funded research
A cheap cancer drug is just as effective and safe in treating a common cause of loss of vision as an expensive alternative, finds research funded by the NIHR Health Technology Assessment (HTA) Programme. The two year study, which published its results in The Lancet, compared anti-cancer drug Avastin (bevacizumab) with Lucentis (ranibizumab), the drug... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - September 26, 2013 Category: American Health Source Type: news

Monthly Ranibizumab Improves Diabetic RetinopathyMonthly Ranibizumab Improves Diabetic Retinopathy
The severity of diabetic retinopathy is more likely to improve and progression to proliferative disease is less likely to happen when diabetic macular edema is treated with monthly ranibizumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Diabetic Macular Edema: Ranibizumab May Offer Good OutcomesDiabetic Macular Edema: Ranibizumab May Offer Good Outcomes
Study's findings must be confirmed in a real-world setting, the investigators warn. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab Effective for Wet Macular DegenerationRanibizumab Effective for Wet Macular Degeneration
Two-year results from the HARBOR trial are in, and they show an individualized treatment approach with ranibizumab is appropriate for treatment-naive patients with age-related macular degeneration. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab, Ranibizumab Improve Vision in Choroidal OsteomaBevacizumab, Ranibizumab Improve Vision in Choroidal Osteoma
Intravitreal injections of antivascular endothelial growth-factor agents are effective in the majority of eyes with choroidal neovascularization. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Lucentis Bests Laser in DME (CME/CE)
(MedPage Today) -- Patients with diabetic macular edema (DME) treated with the costly drug ranibizumab (Lucentis) reported more clinically meaningful improvement in visual functioning than those who received laser treatments alone, according to a new study. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 25, 2013 Category: Consumer Health News Source Type: news

Aflibercept for Exudative AMD Aflibercept for Exudative AMD 
How do patients with exudative AMD with persistent fluid on OCT despite receiving regular ranibizumab and/or bevacizumab respond to aflibercept? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

NHS could save £84m using cheaper drug to prevent blindness, trial finds
Researchers say Avastin is just as good as more-expensive Lucentis for treating wet age-related macular degenerationThe NHS could save more than £84m a year if it used a cheap, unlicensed drug to treat people in danger of going blind rather than the expensive one currently licensed and promoted by leading pharmaceutical companies for the purpose, a ground-breaking trial has shown.Researchers led by Prof Usha Chakravarthy from Queen's University Belfast have finally provided an answer to the controversial question of whether the cancer drug Avastin can safely be used to treat people with wet age-related macular degene...
Source: Guardian Unlimited Science - July 19, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian Pharmaceuticals industry News Health Medical research Society UK news Disability Blindness and visual impairment NHS Business Science Source Type: news

Avastin as Good as Lucentis for AMD (CME/CE)
(MedPage Today) -- Bevacizumab (Avastin) appears to have efficacy similar to that of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration, and monthly administration may offer some advantages over as-needed treatment, randomized trial results showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 19, 2013 Category: Consumer Health News Source Type: news

Ranibizumab Injections for Retinopathy of PrematurityRanibizumab Injections for Retinopathy of Prematurity
A new study reports on the 3-year outcomes of infants with ROP treated with intravitreal ranibizumab injections. Are they effective? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Lucentis approved in EU
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 9, 2013 Category: Drugs & Pharmacology Source Type: news

Novartis’ Lucentis gets EU approval to treat pathologic myopia
The European Commission has approved Novartis’ Lucentis (ranibizumab) for the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Drug Development Technology)
Source: Drug Development Technology - July 8, 2013 Category: Pharmaceuticals Source Type: news

Ranibizumab Approved in EU for Myopia ComplicationRanibizumab Approved in EU for Myopia Complication
A clinical trial has shown that patients with choroidal neovascularization generally experienced better vision after 1 injection of the vascular endothelial growth factor inhibitor. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

EU approves Novartis eye drug for new use
ZURICH (Reuters) - Swiss drugmaker Novartis' eye drug Lucentis has been approved as a treatment for a further condition related to worsening eyesight by the European Union, adding to three other conditions for which it is already approved. (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Pilot Study Has Promising Results For Age-Related Macular Degeneration
There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two drugs either don't work for long or fail to work at all. It's a dead end for treatment, or so it seemed... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

No Proof Of Added Benefit Found For Aflibercept In Wet Age-Related Macular Degeneration
Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 7, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Lucentis® receives positive opinion
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news

Bayer’s AMD drug to rival Lucentis after NICE recommendation
The National Institute of Health and Care Excellence in the UK has recommended Bayer's wet age-related macular degeneration (AMD) drug Eylea in its final draft guidance published today. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 31, 2013 Category: Pharmaceuticals Source Type: news

RVO: Reading Speed Improves With Ranibizumab Injections RVO: Reading Speed Improves With Ranibizumab Injections
Ranibizumab therapy makes a functional difference for patients with retinal vein occlusion, researchers have found. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab Cheaper Than Ranibizumab for Macular DegenerationBevacizumab Cheaper Than Ranibizumab for Macular Degeneration
Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab, Ranibizumab Comparable for Macular DegenerationBevacizumab, Ranibizumab Comparable for Macular Degeneration
Investigators report no difference between the 2 agents for visual acuity at 1 year, but concern lingers over adverse events. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Real-world data highlight transformational outcomes seen with Lucentis®
Novartis has reported that new data with the eye drug Lucentis® (ranibizumab), first licensed in June 2006, is highlighted in a total of 209 abstracts at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 8, 2013 Category: Drugs & Pharmacology Source Type: news

Topol Talks to Ferrara, $3M Breakthrough Prize WinnerTopol Talks to Ferrara, $3M Breakthrough Prize Winner
Dr. Eric Topol talks with Dr. Napoleone Ferrara, recent winner of the Breakthrough Prize in Life Sciences and the researcher whose work led to the synthesis of bevacizumab and ranibizumab. Medscape One-on-One (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 2, 2013 Category: Intensive Care Tags: Internal Medicine Expert Interview Source Type: news

Side Effect Of Retinal Detachment May Be Prevented By Ranibizumab
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Ranibizumab may prevent retinal detachment side effect
(Massachusetts Eye and Ear Infirmary) Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. A new study suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 9, 2013 Category: Global & Universal Source Type: news

Ranibizumab or Bevacizumab in Patients With Neovascular AMDRanibizumab or Bevacizumab in Patients With Neovascular AMD
Is there a particular anti-VEGF agent that works best in neovascular AMD? This new study compares ranibizumab and bevacizumab. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

NCI Grantees Receive Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences recognizes “excellence in research aimed at curing intractable diseases and extending human life.” The inaugural set of prizes, awarded in February 2013 by a not-for-profit corporation dedicated to advancing breakthrough research, are backed by well-known personalities such as Sergey Brin, Google co-founder and his wife, Anne Wojcicki, co-founder of a personal genomics and biotech company 23andMe; Facebook founder Mark Zuckerberg  and his wife, Priscilla Chan; Russian entrepreneur Yuri Milner; and  Art Levinson, chairman of Apple and Genentech. The 11 recip...
Source: NCI Benchmarks - March 8, 2013 Category: Cancer & Oncology Authors: Aleea Farrakh Khan Tags: Scientist Spotlight award Source Type: news

NICE backs drug for diabetic macular oedema
The National Institute for Health and Clinical Excellence has recommended ranibizumab (Lucentis) for treating visual impairment caused by diabetic macular oedema, after its manufacturer Novartis agreed to provide it at a discounted rate. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - March 1, 2013 Category: Nursing Source Type: news

NICE issues final guidance supporting the use of ranibizumab for diabetic macular oedema (TA 274)
Source: NICE Area: Evidence> Guidelines NICE has issued final guidance (TA 274) supporting the use of ranibizumab for treating visual impairment due to diabetic macular oedema (DMO) only if:   . the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and . the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).   NICE conducted a rapid review of the original guidance (TA 237; November 2011) because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses showing ...
Source: NeLM - Guidelines - February 27, 2013 Category: UK Health Source Type: news

NICE costing template for its guidance on ranibizumab for diabetic macular oedema (TA 274)
Source: NICE Area: News NICE has published a costing statement to accompany its guidance on the use of ranibizumab for treating visual impairment due to diabetic macular oedema (TA 274).   The costing report calculates that: "the annual cost associated with implementing this recommendation is estimated as £41,000 for a population of 100,000 based on the standard assumptions in the model once a steady state is reached. There are also anticipated to be non-recurrent costs from treating the prevalent population on implementation of the guideline of around £341,000. It is assumed that people with eli...
Source: NeLM - News - February 27, 2013 Category: Drugs & Pharmacology Source Type: news

Phase III study: Twelve-Month comparison of 0.5 mg or 2.0 mg ranibizumab in patients with wet age-related macular degeneration (HARBOR)
Source: Ophthalmology Area: News Several small studies have suggested the potential of enhanced efficacy with higher 2mg dosing of ranibizumab. The HARBOR study was a 24-month, phase III, randomised, multicentre, double-masked study which evaluated the 12-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly and on an as-needed (PRN) basis in treatment-naïve patients (n=1,098) aged over 50 years with subfoveal neovascular age-related macular degeneration (wet AMD).   Noninferiority (NI) tests with a prespecified NI margin of 4 letters comparing the 0.5 mg PRN with the ...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news

Little Help from Lucentis for Vitreous Hemorrhage (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 5, 2013 Category: Opthalmology Source Type: news

Little Help from Lucentis for Diabetic Eyes (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 1, 2013 Category: Opthalmology Source Type: news

Ranibizumab Fails to Beat Saline in Avoiding VitrectomyRanibizumab Fails to Beat Saline in Avoiding Vitrectomy
Patients with vitreous hemorrhage from proliferative diabetic retinopathy who received intravitreal injections of ranibizumab or saline had about the same rates of vitrectomy by 16 weeks. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

NETAG issues appraisal and recommendation on aflibercept for AMD
Source: NETAG Area: Evidence> Drug Specific Reviews The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose as stated in the...
Source: NeLM - Drug Specific Reviews - January 21, 2013 Category: Drugs & Pharmacology Source Type: news

NICE makes u-turn decision on Lucentis
A UK health watchdog has recommended the use of Lucentis for the treatment of visual impairment caused by diabetic macular oedema (DMO) after manufacturer Novartis dropped the price of the drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 7, 2013 Category: Pharmaceuticals Source Type: news